Biodexa Pharmaceuticals plc - American Depositary Shares BDRX 深 沪

Biodexa Prices $10M Public Offering

Biodexa Pharmaceuticals PLC, (NASDAQ:BDRX) ("Biodexa" or the "Company"), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs,

12-18 21:38

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

Biodexa Pharmaceuticals has named its upcoming Phase 3 study for Familial Adenomatous Polyposis (FAP) as "Serenta." A dedicated website, www.serentatrial.com, has been launched to provide information and resources for patients and healthcare professionals. The study aims to advance eRapa, an oral rapamycin formulation designed to inhibit mTOR and address the challenges associated with current rapamycin treatments.

06-23 12:30

Result of General Meeting

shareholders approved four resolutions. Resolutions 1 and 4 reduce the par value of ordinary shares, while Resolutions 2 and 3 grant the Directors authority to allot ordinary shares non-pre-emptively.

06-11 20:30

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

Biodexa Pharma announced the first patient enrollment in a Phase 2 study of tolimidone for Type 1 Diabetes, conducted by the University of Alberta. Tolimidone aims to improve beta cell function and insulin signaling.

06-04 12:30

Shareholder Update

05-30 12:30

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting

05-22 20:30

Biodexa Pharmaceuticals H1 2024 EPS (0.1p) Vs (3.6)p YoY

For the year six month period ended June 30 Note2024unaudited£'0002023unaudited£'000Revenue -298Research and development costs (2,189)(2,251)Administrative costs (2,034)(2,291)Loss from

2024-09-26 20:41

Biodexa Pharmaceuticals Announces A Ratio Change On Its ADRs From 1 ADS Representing 400 Ordinary Shares, To The New Ratio Of 1 ADR Representing 10,000 Ordinary Shares (1-For-25) ; Effective Date Of The Ratio Change Is Expected To Be October 4,2024.

Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today

2024-09-20 04:33

European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading

11:12 AM EDT, 09/03/2024 (MT Newswires) -- European equities traded in the US as American depositary receipts were falling late Tuesday morning, declining 1.60% to 1,457.09 on the S&P Europe Select ADR Index. From continental Europe, the gainers were led by pharmaceutical company Sanofi (SNY) and se...

2024-09-03 23:12

12 Health Care Stocks Moving In Monday's After-Market Session

Gainers Conduit Pharmaceuticals (NASDAQ:CDT) stock increased by 27.4% to $0.16 during Monday's after-market session. The company's market cap stands at $15.0 million. TNF Pharmaceuticals (NASDAQ:TNFA) stock moved upwards by 18.82% to $2.02. The market value of their outstanding shares is at $4.7 mil...

2024-09-03 04:31